475 related articles for article (PubMed ID: 11072169)
1. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
[TBL] [Abstract][Full Text] [Related]
2. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):17-22. PubMed ID: 11163493
[TBL] [Abstract][Full Text] [Related]
3. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Wilder RB; Rodriguez MA; Tucker SL; Ha CS; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):743-9. PubMed ID: 11395243
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
Krol AD; Berenschot HW; Doekharan D; Henzen-Logmans S; van der Holt B; van 't Veer MB
Radiother Oncol; 2001 Mar; 58(3):251-5. PubMed ID: 11230885
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
6. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
7. Stage I non-Hodgkin's lymphoma treated with doxorubicin-containing chemotherapy with or without radiotherapy.
Villikka K; Muhonen T; Ristamäki R; Teerenhovi L; Joensuu H
Acta Oncol; 1997; 36(6):619-24. PubMed ID: 9408153
[TBL] [Abstract][Full Text] [Related]
8. Outcome analysis for stage IE and IIE thyroid lymphoma.
DiBiase SJ; Grigsby PW; Guo C; Lin HS; Wasserman TH
Am J Clin Oncol; 2004 Apr; 27(2):178-84. PubMed ID: 15057158
[TBL] [Abstract][Full Text] [Related]
9. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma.
Kamath SS; Marcus RB; Lynch JW; Mendenhall NP
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):563-8. PubMed ID: 10348285
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
Miller TP; Dahlberg S; Cassady JR; Adelstein DJ; Spier CM; Grogan TM; LeBlanc M; Carlin S; Chase E; Fisher RI
N Engl J Med; 1998 Jul; 339(1):21-6. PubMed ID: 9647875
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
[TBL] [Abstract][Full Text] [Related]
14. Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: long-term results for 96 patients with tumors > 5 cm.
Munck JN; Dhermain F; Koscielny S; Girinsky T; Carde P; Bosq J; Decaudin D; Juliéron M; Cosset JM; Hayat M
Ann Oncol; 1996 Nov; 7(9):925-31. PubMed ID: 9006743
[TBL] [Abstract][Full Text] [Related]
15. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
[TBL] [Abstract][Full Text] [Related]
16. Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study.
Willich NA; Reinartz G; Horst EJ; Delker G; Reers B; Hiddemann W; Tiemann M; Parwaresch R; Grothaus-Pinke B; Kocik J; Koch P
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):895-901. PubMed ID: 10705011
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy and radiotherapy for non-Hodgkin's lymphomas of the nasal cavity].
Nie DH; Hu WH; Gao YH; Wu Y; Zhang SP
Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):312-4. PubMed ID: 15312373
[TBL] [Abstract][Full Text] [Related]
19. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
Bessell EM; Burton A; Haynes AP; Glaholm J; Child JA; Cullen MH; Davies JM; Smith GM; Ellis IO; Jack A; Jones EL;
Ann Oncol; 2003 Feb; 14(2):258-67. PubMed ID: 12562653
[TBL] [Abstract][Full Text] [Related]
20. Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma.
Wilder RB; Romaguera JE; Tucker SL; Ha CS; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Feb; 94(3):601-5. PubMed ID: 11857290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]